Azithromycin 1.5% ophthalmic solution: Efficacy and treatment modalities in chronic blepharitis

Arquivos Brasileiros de Oftalmologia

Volumn 75, Issue 3, 2012, Pages 178-182

  Fadlallah, Ali ^a   El Rami, Hala ^a   Fahd, Daoud ^b   Dunia, Ibrahim ^b,c   Bejjani, Riad ^a,b,c   Chlela, Elie ^a   Waked, Naji ^a   Jabbour, Elyse ^a   Fahed, Sharbel ^b,c  

^a SAINT JOSEPH UNIVERSITY   (Lebanon)

^b Ophthalmic Consultants of Beirut Jal El Dib ^*  (Lebanon)

^c LEBANESE AMERICAN UNIVERSITY   (Lebanon)

Author keywords

Azithromycin administration dosage; Blepharitis drug therapy; Chronic disease; Meibomian glands; Ophthalmic solutions

Indexed keywords

ANTIINFECTIVE AGENT; AZITHROMYCIN; EYE DROPS;

ADOLESCENT; ADULT; AGED; ARTICLE; BLEPHARITIS; CHRONIC DISEASE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; LAVAGE; MALE; METHODOLOGY; MIDDLE AGED; NONPARAMETRIC TEST; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TIME; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; BLEPHARITIS; CHRONIC DISEASE; FEMALE; HUMANS; MALE; MIDDLE AGED; OPHTHALMIC SOLUTIONS; PROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC; THERAPEUTIC IRRIGATION; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84867145950     PISSN: 00042749     EISSN: 16782925     Source Type: Journal    
DOI: 10.1590/S0004-27492012000300006     Document Type: Article

References (25)

1. Huber-Spitzy V, Baumgartner I, Bohler-Sommeregger K, Grabner G. Blepharitis - a diag - nostic and therapeutic challenge. A report on 407 consecutive cases. Graefes Arch Clin Exp Ophthalmol. 1991;229(3):224-7.
2. Au YK, Jensen HG, Rowsey J, Reynolds M. Coagulase-negative staphylococci in conjunctivitis and blepharitis. Yan Ke Xue Bao. 1993;9(3):129-35.
3. Freidlin J, Acharya N, Lietman TM, Cevallos V, Whitcher JP, Margolis TP. Spectrum of eye disease caused by methicillin-resistant Staphylococcus aureus. Am J Ophthalmol. 2007;144(2):313-5.
4. Oto S, Aydin P, Ciftcioglu N, Dursun D. Slime production by coagulase-negative staphy lococci isolated in chronic blepharitis. Eur J Ophthalmol. 1998;8(1):1-3.
5. John T, Shah AA. Use of azithromycin ophthalmic solution in the treatment of chronic mixed anterior blepharitis. Ann Ophthalmol (Skokie). 2008;40(2):68-74.
6. Luchs J. Efficacy of topical azithromycin ophthalmic solution 1% in the treatment of posterior blepharitis. Adv Ther. 2008;25(9):858-70.
7. Trattler WB KK, Haque R, Zink RC. Topical azithromycin improves blepharitis signs and symptoms. In: Annual Meeting of American Society of Cataract and Refractive Surgery. San Francisco; ASCRS; 3-8 april 2009.
8. Akpek EK, Vittitow J, Verhoeven RS, Brubaker K, Amar T, Powell KD, et al. Ocular surface distribution and pharmacokinetics of a novel ophthalmic 1% azithromycin formulation. J Ocul Pharmacol Ther. 2009;25(5):433-9.
9. Amar T, Caillaud T, Elena PP. Ocular pharmacokinetic study following single and multiple azithromycin administrations in pigmented rabbits. Curr Eye Res. 2008;33(2):149-58.
10. Chiambaretta F, Garraffo R, Elena PP, Pouliquen P, Delval L, Rigal D, et al. Tear concentrations of azithromycin following topical administration of a single dose of azithromycin 0.5%, 1.0%, and 1.5% eyedrops (T1225) in healthy volunteers. Eur J Opht halmol. 2008;18(1):13-20.
11. Torkildsen G, O'Brien TP. Conjunctival tissue pharmacokinetic properties of topical azithromycin 1% and moxifloxacin 0.5% ophthalmic solutions: a single-dose, randomized, open-label, active-controlled trial in healthy adult volunteers. Clin Ther. 2008;30(11):2005-14.
12. Wang MG, Zhang YY, Zhu DM, Zhang J, Shi YG. Postantibiotic effects of eleven antimicrobials on five bacteria. Acta Pharmacol Sin. 2001;22(9):804-8.
13. Retsema J, Fu W. Macrolides: structures and microbial targets. Int J Antimicrob Agents. 2001;18 Suppl 1:3-10.
14. Abelson MB, Heller W, Shapiro AM, Si E, Hsu P, Bowman LM; AzaSite Clinical Study Group. Clinical cure of bacterial conjunctivitis with azithromycin 1%: vehicle-controlled, double-masked clinical trial. Am J Ophthalmol. 2008;145(6):959-65.
15. Cochereau I, Meddeb-Ouertani A, Khairallah M, et al. 3-day treatment with azithromycin 1.5% eye drops versus 7-day treatment with tobramycin 0.3% for purulent bacterial conjunctivitis: multicentre, randomised and controlled trial in adults and chil dren. Br J Ophthalmol. 2007;91(4):465-9.
16. BenEzra D. Blepharitis and conjunctivitis. Guidelines for diagnosis and treatment. Jerusalem, Israel: Editorial Glosa; 2006.
17. Lemp MA, Nichols KK. Blepharitis in the United States 2009: a survey-based perspec- tive on prevalence and treatment. Ocul Surf. 2009;7(Suppl 2):S1-14.
18. Nelson JD, Shimazaki J, Benitez-del-Castillo JM, Craig JP, McCulley JP, Den S, et al. The international workshop on meibomian gland dysfunction: report of the definition and classification subcommittee. Invest Ophthalmol Vis Sci. 2011;52(4):1930-7.
19. AzaSite (azithromycin ophthalmic solution). Prescribing information. Inspire Pharmaceuticals, Durham, NC2011.
20. Friedlaender MH, Protzko E. Clinical development of 1% azithromycin in DuraSite, a to pical azalide anti-infective for ocular surface therapy. Clin Ophthalmol. 2007;1(1):3-10.
21. Crean C, Vittitow, J, Zink, RC. Comparison of Azasite and azithromycin 1% for bacterial conjunctivitis. In: Annual Meeting of American Society of Cataract and Refractive Surgery. Chicago; ASCRS; 4-9 april 2008.
22. Azyter (azithromycin ophthalmic solution). Prescribing information. Thea laboratories, Clermont-Ferrand, France, 2010.
23. Haque RM, Torkildsen GL, Brubaker K, Zink RC, Kowalski RP, Mah FS, et al. Multicenter open-label study evaluating the efficacy of azithromycin ophthalmic solution 1% on the signs and symptoms of subjects with blepharitis. Cornea. 2010;29(8):871-7.
24. Opitz DL, Tyler KF. Efficacy of azithromycin 1% ophthalmic solution for treatment of ocular surface disease from posterior blepharitis. Clin Exp Optom. 2011;94(2):200-6.
25. Foulks GN, Borchman D, Yappert M, Kim SH, McKay JW. Topical azithromycin therapy for meibomian gland dysfunction: clinical response and lipid alterations. Cornea. 2010;29(7):781-8.